Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):40–45. doi: 10.1038/bjc.1998.439

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.

A Franzke 1, M Probst-Kepper 1, J Buer 1, S Duensing 1, R Hoffmann 1, F Wittke 1, M Volkenandt 1, A Ganser 1, J Atzpodien 1
PMCID: PMC2062938  PMID: 9662248

Abstract

Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into several biological subgroups. Pretreatment serum levels of soluble adhesion molecules and various clinical parameters in cutaneous metastatic malignant melanoma were evaluated to determine their prognostic value. In this study pretreatment serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble endothelial leukocyte adhesion molecule 1 (sE-selectin) and multiple clinical factors were assessed in relation to overall survival of 97 consecutive patients with metastatic cutaneous malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, both univariate and multivariate Cox proportional-hazards models were used. Elevated pretreatment serum levels of sVCAM-1 (P < 0.005) and of lactate dehydrogenase (P < 0.002) were rendered statistically independent and were significantly associated with unfavourable outcome. Patients were assigned to one of three risk categories (low, intermediate and high) according to a cumulative risk score defined as the function of the sum of these two variables. There were significant differences in overall survival (P < 0.0001) between low- (n = 53, 5-year survival probability of 23.3%), intermediate- (n = 29, 5-year survival probability of 9.9%) and high-risk (n = 15) patients. Elevated pretreatment serum levels of sVCAM-1 and of lactate dehydrogenase correlate with poor outcome in metastatic cutaneous malignant melanoma. These data support risk stratification for future therapeutic trials and identify factors that need to be validated in prospective studies and may potentially influence decision-making in palliative management of patients with disseminated cutaneous malignant melanoma.

Full text

PDF
40

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Lopez Hänninen E., Kirchner H., Franzke A., Körfer A., Volkenandt M., Duensing S., Schomburg A., Chaitchik S., Poliwoda H. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995 Jun;31A(6):876–881. doi: 10.1016/0959-8049(94)00459-5. [DOI] [PubMed] [Google Scholar]
  2. Balch C. M., Soong S. J., Murad T. M., Smith J. W., Maddox W. A., Durant J. R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983 Feb;1(2):126–134. doi: 10.1200/JCO.1983.1.2.126. [DOI] [PubMed] [Google Scholar]
  3. Banks R. E., Gearing A. J., Hemingway I. K., Norfolk D. R., Perren T. J., Selby P. J. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993 Jul;68(1):122–124. doi: 10.1038/bjc.1993.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fortis C., Galli L., Consogno G., Citterio G., Matteucci P., Scaglietti U., Bucci E. Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol. 1995 Aug;76(2):142–147. doi: 10.1006/clin.1995.1108. [DOI] [PubMed] [Google Scholar]
  5. Frenette P. S., Wagner D. D. Adhesion molecules--Part 1. N Engl J Med. 1996 Jun 6;334(23):1526–1529. doi: 10.1056/NEJM199606063342308. [DOI] [PubMed] [Google Scholar]
  6. Garofalo A., Chirivi R. G., Foglieni C., Pigott R., Mortarini R., Martin-Padura I., Anichini A., Gearing A. J., Sanchez-Madrid F., Dejana E. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res. 1995 Jan 15;55(2):414–419. [PubMed] [Google Scholar]
  7. Gearing A. J., Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993 Oct;14(10):506–512. doi: 10.1016/0167-5699(93)90267-O. [DOI] [PubMed] [Google Scholar]
  8. Glass A. G., Hoover R. N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989 Oct 20;262(15):2097–2100. [PubMed] [Google Scholar]
  9. Harning R., Mainolfi E., Bystryn J. C., Henn M., Merluzzi V. J., Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991 Sep 15;51(18):5003–5005. [PubMed] [Google Scholar]
  10. Heimdal K., Hannisdal E., Gundersen S. Regression analyses of prognostic factors in metastatic malignant melanoma. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1219–1223. doi: 10.1016/0277-5379(89)90418-5. [DOI] [PubMed] [Google Scholar]
  11. Koh H. K. Cutaneous melanoma. N Engl J Med. 1991 Jul 18;325(3):171–182. doi: 10.1056/NEJM199107183250306. [DOI] [PubMed] [Google Scholar]
  12. Kunter U., Buer J., Probst M., Duensing S., Dallmann I., Grosse J., Kirchner H., Schluepen E. M., Volkenandt M., Ganser A. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 1996 May 1;88(9):590–594. doi: 10.1093/jnci/88.9.590. [DOI] [PubMed] [Google Scholar]
  13. Mould A. P., Askari J. A., Craig S. E., Garratt A. N., Clements J., Humphries M. J. Integrin alpha 4 beta 1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. J Biol Chem. 1994 Nov 4;269(44):27224–27230. [PubMed] [Google Scholar]
  14. Newman W., Beall L. D., Carson C. W., Hunder G. G., Graben N., Randhawa Z. I., Gopal T. V., Wiener-Kronish J., Matthay M. A. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol. 1993 Jan 15;150(2):644–654. [PubMed] [Google Scholar]
  15. Piali L., Fichtel A., Terpe H. J., Imhof B. A., Gisler R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med. 1995 Feb 1;181(2):811–816. doi: 10.1084/jem.181.2.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pigott R., Dillon L. P., Hemingway I. H., Gearing A. J. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992 Sep 16;187(2):584–589. doi: 10.1016/0006-291x(92)91234-h. [DOI] [PubMed] [Google Scholar]
  17. Rice G. E., Bevilacqua M. P. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science. 1989 Dec 8;246(4935):1303–1306. doi: 10.1126/science.2588007. [DOI] [PubMed] [Google Scholar]
  18. Schadendorf D., Heidel J., Gawlik C., Suter L., Czarnetzki B. M. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst. 1995 Mar 1;87(5):366–371. doi: 10.1093/jnci/87.5.366. [DOI] [PubMed] [Google Scholar]
  19. Sirott M. N., Bajorin D. F., Wong G. Y., Tao Y., Chapman P. B., Templeton M. A., Houghton A. N. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993 Nov 15;72(10):3091–3098. doi: 10.1002/1097-0142(19931115)72:10<3091::aid-cncr2820721034>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  20. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991 Nov 16;338(8777):1227–1229. doi: 10.1016/0140-6736(91)92100-g. [DOI] [PubMed] [Google Scholar]
  21. Xerri L., Grob J. J., Battyani Z., Gouvernet J., Hassoun J., Bonerandi J. J. NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer. 1994 Dec;70(6):1224–1228. doi: 10.1038/bjc.1994.477. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES